Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus
- PMID: 26762471
- DOI: 10.1177/0961203315625460
Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus
Abstract
Objectives: To investigate both the prevalence and clinical characteristics of serositis in Chinese patients with systemic lupus erythematosus (SLE) in a large cohort in the Chinese SLE Treatment and Research group (CSTAR) database.
Methods: A prospective cross-sectional study of patients with SLE was conducted based on the data from the CSTAR registry. Serositis was defined according to the 1999 revised American College of Rheumatology (ACR) criteria for SLE - that is, pleuritis/pleural effusion and/or pericarditis/pericardial effusion detected by echocardiography, chest X-ray or chest computerized tomography (CT) scan. Peritonitis/peritoneal effusion were confirmed by abdominal ultrasonography. We analysed the prevalence and clinical associations of serositis with demographic data, organ involvements, laboratory findings and SLE disease activity.
Results: Of 2104 patients with SLE, 345 were diagnosed with serositis. The prevalence of lupus nephritis (LN), interstitial lung disease and pulmonary arterial hypertension, as well as the presence of leukocytopenia, thrombocytopenia, hypocomplementemia and anti-dsDNA antibodies was significantly higher in patients with serositis (P < 0.05). Significantly higher SLE disease activity scores were found in patients with serositis compared to those patients without serositis (P < 0.05). Lupus-related peritonitis had similar clinical manifestations and laboratory profiles as serositis caused by SLE.
Conclusions: There is a significant association of nephropathy, interstitial lung disease, pulmonary arterial hypertension, hypocomplementemia, leukocytopenia, thrombocytopenia and elevated anti-dsDNA antibodies with serositis. The results suggest that higher SLE disease activity contributes to serositis development, and should be treated aggressively.
Keywords: Prevalence; clinical significance; serositis; systemic lupus erythematosus.
© The Author(s) 2016.
Similar articles
-
Serositis related to systemic lupus erythematosus: prevalence and outcome.Lupus. 2005;14(10):822-6. doi: 10.1191/0961203305lu2187oa. Lupus. 2005. PMID: 16302677
-
Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.Lupus. 2014 Sep;23(10):1085-91. doi: 10.1177/0961203314527366. Epub 2014 Mar 20. Lupus. 2014. PMID: 24651670
-
Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus.PLoS One. 2019 Nov 20;14(11):e0225516. doi: 10.1371/journal.pone.0225516. eCollection 2019. PLoS One. 2019. PMID: 31747435 Free PMC article.
-
Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.Semin Arthritis Rheum. 2018 Oct;48(2):198-204. doi: 10.1016/j.semarthrit.2018.01.010. Epub 2018 Jan 31. Semin Arthritis Rheum. 2018. PMID: 29550111 Free PMC article.
-
Risk factors of systemic lupus erythematosus patients with pulmonary arterial hypertension: A systematic review and meta-analysis.Medicine (Baltimore). 2023 Dec 22;102(51):e36654. doi: 10.1097/MD.0000000000036654. Medicine (Baltimore). 2023. PMID: 38134088 Free PMC article.
Cited by
-
Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension.Front Med (Lausanne). 2021 Mar 4;8:618486. doi: 10.3389/fmed.2021.618486. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33748158 Free PMC article.
-
The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV).Clin Rheumatol. 2022 May;41(5):1371-1379. doi: 10.1007/s10067-021-06034-6. Epub 2022 Jan 27. Clin Rheumatol. 2022. PMID: 35083563
-
CircELK4 Contributes to Lupus Nephritis by Acting as a miR-27b-3p Sponge to Regulate STING/IRF3/IFN-I Signaling.Inflammation. 2021 Oct;44(5):2106-2119. doi: 10.1007/s10753-021-01487-y. Epub 2021 Jun 5. Inflammation. 2021. PMID: 34091806
-
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study.Arthritis Res Ther. 2024 Mar 12;26(1):67. doi: 10.1186/s13075-024-03305-w. Arthritis Res Ther. 2024. PMID: 38475924 Free PMC article.
-
The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.Rheumatol Int. 2017 Feb;37(2):305-311. doi: 10.1007/s00296-016-3630-0. Epub 2016 Dec 20. Rheumatol Int. 2017. PMID: 27999942
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical